Details for New Drug Application (NDA): 212304
✉ Email this page to a colleague
NDA 212304 describes ADLARITY, which is a drug marketed by Corium and is included in one NDA. There are eleven patents protecting this drug. Additional details are available on the ADLARITY profile page.
The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.
The generic ingredient in ADLARITY is donepezil hydrochloride. There are thirty-two drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.
Summary for 212304
| Tradename: | ADLARITY |
| Applicant: | Corium |
| Ingredient: | donepezil hydrochloride |
| Patents: | 11 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYSTEM;TRANSDERMAL | Strength | 5MG/DAY | ||||
| Approval Date: | Mar 11, 2022 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Mar 11, 2025 | ||||||||
| Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jul 26, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jul 26, 2037 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
